NOVO NORDISK CEO said semaglutide's regulatory data protection runs through Q2 next year; generics are expected to begin entering the market thereafter.

2026-06-16

NOVO NORDISK CEO said semaglutide's regulatory data protection runs through Q2 next year; generics are expected to begin entering the market thereafter.